Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novavax, Inc. (NVAX)

6.021   0.001 (0.02%) 03-22 14:40
Open: 6.07 Pre. Close: 6.02
High: 6.1607 Low: 5.9
Volume: 2,283,603 Market Cap: 519(M)

Technical analysis

as of: 2023-03-22 2:19:36 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 9.95     One year: 12
Support: Support1: 5.67    Support2: 4.72
Resistance: Resistance1: 8.52    Resistance2: 10.27
Pivot: 6.52
Moving Average: MA(5): 6     MA(20): 7.02
MA(100): 12.89     MA(250): 32.07
MACD: MACD(12,26): -1.1     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 14.1     %D(3): 10.6
RSI: RSI(14): 30.9
52-week: High: 82.3  Low: 5.67
Average Vol(K): 3-Month: 6,741 (K)  10-Days: 6,187 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NVAX ] has closed above bottom band by 30.7%. Bollinger Bands are 62% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.37 - 6.39 6.39 - 6.42
Low: 5.86 - 5.89 5.89 - 5.91
Close: 5.98 - 6.02 6.02 - 6.06

Company Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Headline News

Mon, 20 Mar 2023
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats - Yahoo Finance

Thu, 09 Mar 2023
Premarket Mover: Novavax Inc (NVAX) Down 1.31% - InvestorsObserver

Wed, 08 Mar 2023
Novavax Inc. (NVAX) Stock: A Closer Look at the Moving Averages - The News Heater

Sun, 05 Mar 2023
Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook - Simply Wall St

Thu, 02 Mar 2023
Novavax Announces Grant of Inducement Awards Pursuant to ... - Novavax Investor Relations

Wed, 01 Mar 2023
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock ... - Nasdaq

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 85 (M)
Shares Float 78 (M)
% Held by Insiders 2 (%)
% Held by Institutions 47.2 (%)
Shares Short 30,910 (K)
Shares Short P.Month 24,470 (K)

Stock Financials

EPS -7.27
EPS Est Next Qtl -0.16
EPS Est This Year -0.63
EPS Est Next Year -0.56
Book Value (p.s.) 8.84
Profit Margin (%) -71.6
Operating Margin (%) -66.4
Return on Assets (ttm) -31.8
Return on Equity (ttm) 0
Qtrly Rev. Growth 310.7
Gross Profit (p.s.) -16.36
Sales Per Share 21.76
EBITDA (p.s.) -14.12
Qtrly Earnings Growth 0
Operating Cash Flow -641 (M)
Levered Free Cash Flow -1,490 (M)

Stock Valuations

PE Ratio -0.85
PEG Ratio -0.1
Price to Book value 0.69
Price to Sales 0.28
Price to Cash Flow -0.82

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-05-09
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.